Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Byoung Yong Shim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B (Nature Communications, (2025), 16, 1, (6393), 10.1038/s41467-025-61420-x)
Lee, K. W., Mahalingam, D., Shim, B. Y., Kim, I. H., Oh, D. Y., Uronis, H., Sym, S. J., Sonbol, M., Almhanna, K., Tejani, M. A., Kang, B., Kagey, M. H., Stilian, M., Jia, C., Sirard, C. A., Altura, R., Ajani, J. A. & Klempner, S. J., Dec 2026, In: Nature Communications. 17, 1, 1437.Research output: Contribution to journal › Comment/debate
Open Access -
Autophagy inhibition enhances sensitivity of alpelisib in PI3K–mutated non-small cell lung cancer
Kim, J., Shrestha, C., Kim, T. W., Lee, S. B., Lee, G., Jung, D., Hwang, M., Kang, S., Park, H. S., Kim, H., An, H. J., Chae, D., Shim, B. Y. & Kim, J., Nov 2025, In: Biomedicine and Pharmacotherapy. 192, 118620.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Lee, K. W., Mahalingam, D., Shim, B. Y., Kim, I. H., Oh, D. Y., Uronis, H., Sym, S. J., Sonbol, M., Almhanna, K., Tejani, M. A., Kang, B., Kagey, M. H., Stilian, M., Jia, C., Sirard, C. A., Ajani, J. A. & Klempner, S. J., Dec 2025, In: Nature Communications. 16, 1, 6393.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Erratum to: “Autophagy inhibition enhances sensitivity of alpelisib in PI3K–mutated non-small cell lung cancer” (Biomedicine & Pharmacotherapy, (2025), 192, C, (118620), (S0753332225008145), 10.1016/j.biopha.2025.118620)
Kim, J., Shrestha, C., Kim, T. W., Lee, S. B., Lee, G., Jung, D., Hwang, M., Kang, S., Park, H. S., Kim, H., An, H. J., Chae, D., Shim, B. Y. & Kim, J., Nov 2025, In: Biomedicine and Pharmacotherapy. 192, 118651.Research output: Contribution to journal › Comment/debate
Open Access -
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
Zhou, Q., Yu, Y., Xing, L., Cheng, Y., Wang, Y., Pan, Y., Fan, Y., Shi, J., Zhang, G., Cui, J., Zhou, J., Song, Y., Zhuang, W., Ma, Z., Hu, Y., Li, G., Dong, X., Feng, J., Lu, S. & Wu, J. & 20 others, , 10 Jan 2025, In: Med. 6, 1, 100513.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations